Clarity Pharmaceuticals announced the Phase II US-based diagnostic Cu SAR-Bombesin trial (SABRE NCT05407311)1 for patients with prostate cancer has reached its 50% recruitment milestone, with 25 out of 50 participants enrolled and imaged. SABRE (Copper-64 SAR-Bombesin in Biochemical Recurrence of prostate cancer) is a Phase II Positron Emission Tomography (PET) imaging trial of participants with PSMA-negative biochemical recurrence (BCR) of prostate cancer following definitive therapy. It is a multi-centre, single arm, non-randomised, open-label trial of 64Cu-labelled SAR-Bombesin in 50 participants.

The primary objectives of the trial are to investigate safety and tolerability of the product as well as its ability to correctly detect recurrence of prostate cancer.